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Abstract. Stereotactic radiosurgery (SRS), which delivers high doses of
irradiation in a single or few shots to small targets, has been a standard
of care for brain metastases. While very effective, SRS currently requires
manually intensive delineation of tumors. In this work, we present a deep
learning approach for automated detection and segmentation of brain
metastases using multimodal imaging and ensemble neural networks. In
order to address small and multiple brain metastases, we further pro-
pose a volume-aware Dice loss which optimizes model performance using
the information of lesion size. This work surpasses current benchmark
levels and demonstrates a reliable AI-assisted system for SRS treatment
planning for multiple brain metastases.
Keywords: Brain Metastases · Radiosurgery · Deep learning.
1 Introduction
Brain metastases (BMs) are the most common intracranial tumors in adults (10
times more common than primary brain tumors) and occur in around 20% of
all patients with cancer [5]. The treatment options for brain metastases include
craniotomy, chemotherapy, whole brain radiation therapy, and stereotactic ra-
diosurgery (SRS). Among all the options, SRS has been playing a critical role in
the treatment of brain metastases as recent studies have shown that SRS leads
to better treatment outcomes [10]. By delivering high doses of irradiation in a
single or few shots to small targets, SRS effectively destroys tumors without
damaging surrounding tissues and has been proved to be beneficial in the local
tumor control and post-operative neurocognitive function [3].
As SRS requires precise delineation of tumor margins, target segmentation
(contouring) for BMs is performed manually by the radiation oncologist or neuro-
surgeon on magnetic resonance images (MRI) and computed tomography (CT)
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images of the brain. However, such manually contouring process can be very
time-consuming and suffer from large inter and intra-reader variability [11].
Driven by the ever-increasing capability of deep learning, automated segmen-
tation of BMs using neural networks has been recently proposed [1,6]. Previous
works on computer-aided segmentation of BMs used only MRI as an imaging
input. While MRI provides superior ability to characterize neural tissue and
the brain structure, MRI is prone to have the problems of spatial distortion
and motion artifacts, which can lead to inaccuracy in SRS. CT, on the other
hand, is lack of soft tissue contrast but provides a direct measurement of elec-
tron densities for radiation dose calculations and has excellent spatial fidelity.
Consequently, co-registration between MRI and CT modalities is recommended
for precise stereotactic applications [9].
Many previous works on automated segmentation of brain tumors focused
on multiforme glioblastoma and glioma, such as BraTS dataset [7], and aims to
optimize Dice similarity coefficient (DSC) [8]. Segmentation of brain metastases
is more challenging as metastatic lesions can be very small (< 1000 mm3) and a
large brain metastasis can coexist with multiple small lesions. Conventional DSC
is thus not an ideal metric to evaluate brain metastases segmentation because
it would be dominant by the large lesion but ignore small metastases. Unfor-
tunately, small BMs are much crucial to SRS since they are more likely to be
missed by clinicians.
In this paper, we aim to utilize deep neural networks for automated detection
and segmentation of brain metastases. Specifically, we present a deep learning-
based system for brain metastases detection and segmentation using multimodal
imaging (MRI+CT) and ensemble neural networks, which produces a more re-
liable result than that would be achieved by a single image modality and/or a
single neural network. To address the challenge of small BMs, we further propose
a volume-aware Dice loss (`vol-dice), which leverages the information of lesion size
to optimize overall segmentation.
2 Methods
2.1 Volume-Aware Dice Loss
The Dice loss (`dice), which aims to optimize DSC, has been widely used as a
loss function in medical image segmentation task [8] and can be expressed as:
`dice (g,p) = − 2g
>p + 
p>p + g>g + 
, (1)
where p ∈ [0, 1]N and g ∈ {0, 1}N are the predicted probability vector and the
ground truth binary vector for N voxels, respectively.  is a smoothing constant
to avoid the denominator being zero.
For binary segmentation problems with similar sizes of lesions, using `dice
as the objective function is a fair option as it is normalized by the number of
foreground pixels. However, `dice is not an ideal choice when multiple targets are
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present with the same label but with different sizes, since the loss will be dom-
inant by the larger targets. To address the issue, we proposed a Volume-Aware
Dice Loss (`vol-dice) that optimizes the overall segmentation using the information
of lesion size. `vol-dice can be formulated as:
`vol-dice (g,p |W ) = − Cg
>Wp + 
p>p + g>Wg + 
, (2)
where W ∈ RN×N is a diagonal matrix that Wii is a weight related to the
volume of the tumor containing the i-th voxel in the ground truth, denoted
by volume (i). C := 1 + g>g/g>Wg is a normalization constant such that the
maximum of `vol-dice is one. In this paper, we consider the form:
Wii =

(
λ
volume(i)
)1/2
volume (i) 6= 0,
0 otherwise
,
where λ is a reweighting hyper-parameter and can be defined as follows.
1. Constant Reweight (CR): λ is a constant (λc), such that the weights are
simply proportional to the inverse of the square root of tumor volume.
2. Batch Reweight (BR): λ is the largest tumor volume in each batch (λl);
e.g. if the largest tumor in one batch has 1500 voxels, another small tumor
with 60 voxels will have a weight of
√
1500/60 = 5.
To demonstrate the effects of `vol-dice, assume a brain image volume with
three ground-truth tumors, each with 1800, 450 and 200 voxels. Using the batch
reweight `vol-dice, each tumor will have weights 1, 2 and 3, respectively. Suppose
the model perfectly predicts the two larger tumors but fails to detect the smallest
one. Under such a scenario, `dice is calculated as − 2×(1800+450)(1800+450+200)+(1800+450) =
−0.957 and `vol-dice is − C×(1800+450×2)(1800+450×2+200×3)+(1800+450) = −0.847, where C = 1 +
2450
3300 . It illustrates that `vol-dice is more sensitive to the small structures.
2.2 Deep Learning Framework
While the current benchmark for brain metastases segmentation employs MRI
imaging only [1,6], CT imaging is an essential reference for clinical treatment
planning due to its spatial accuracy. We thus proposed a deep learning framework
using multimodal imaging (MRI+CT) and ensemble neural networks for brain
metastases detection and segmentation. The framework is shown in Figure 1.
For the ensemble model, we explored two different architectures—3D U-Net and
DeepMedic.
3D U-Net 3D U-Net [2] is an extension of the original U-Net by replacing all
the 2D operations with 3D counterparts. We added one block in addition to
the original implementation (number of feature maps: 32, 64, 128, 256, 512 with
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Fig. 1. Proposed deep learning framework with multimodal imaging and ensemble
networks.
convolution kernel size 3×3×3 and max-pooling size 2×2×1). We took a full
size of the axial-view images and randomly sampled 8 consecutive slices on the
vertical axis, resulting in input images size of 512×512×8×2 (height × width ×
number of slices × number of imaging modality). We set a limit to ensure that in
each epoch, at least 70% of the samples should contain tumor labels. All the 3D
U-Net models were trained using a rmsprop optimizer, with learning rate 10−3,
batch size of 1, over 300 epochs on an NVIDIA V100 GPU. The best weights on
the validation set was used to evaluate the final results on the test set.
DeepMedic DeepMedic [4] is originally designed for brain tumor segmentation
on multi-channel MRI and also had been applied to BMs [1,6]. It consists of
multiple parallel pathways—one branch takes small patches from full resolution
images as input and the others utilizes subsampled-version of the images. Dif-
ferent from the original paper, the DeepMedic architecture we used contained 3
parallel convolutional pathways, one of which was with normal image resolution
and the other two of which were with low resolution using down-sampling fac-
tors of 3 and 5. There were 11 layers in the network, the first 8 of which were
convolutional layers (number of feature maps: 30, 30, 40, 40, 40, 40, 50, 50 with
3×3×3 kernels) and the last 3 of which were fully connected layers (with 250
feature maps per layer). The network was trained using a rmsprop optimizer,
with learning rate 10−3, minimizing the cross-entropy loss over 35 epochs.
Ensemble Model 3D U-Net and DeepMedic were trained separately with dif-
ferent hyperparameters and different objective functions to maximize the ca-
pability of the ensemble model. While U-Net utilized the full field of view for
each image slice and addressed overall tumor segmentation, DeepMedic lever-
aged image segments during model training and focused on small metastases.
Furthermore, U-Net was trained to optimize DSC and DeepMedic was set to
minimize cross-entropy loss. At testing time, each model individually generated
probability maps of brain metastases. An ensemble confidence map was then
created by calculating the average of the predictions of both models.
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3 Experiments and Results
Data
The primary cohort for model training and testing consists of 305 patients with
864 brain metastases (median volume 760 mm3, range 3-110,000 mm3) treated
by CyberKnife G4 system in a single medical center. Each case contains vol-
ume masks of brain tumors delineated by an attending radiation oncologist or
neurosurgeon on associated CT and T1-weighted MRI scan with contrast. The
dataset was split into training (80%), validation (10%), and test set (10%) ran-
domly. To evaluate the model robustness and generalizability, we collected an
additional batch of test set from the same institution, containing 36 patients
with 96 metastases (median volume 829 mm3). The results presented in this
paper are the average of the two test sets.
For each case, after rigid image registration between CT and MRI image vol-
umes, each slice was resized into 512×512 pixels with the resolution of 0.6mm ×
0.6mm, while slice thickness was resampled to 2mm. Brain window and adaptive
histogram equalization were applied to the CT and MRI images slice-by-slice,
respectively. All the image volumes were then standardized with zero-mean and
unit-variance normalization.
3.1 Volume-Aware Dice Loss
`vol-dice with different reweight strategies We evaluated the efficacy of
`vol-dice on the 3D U-Net. A standard 3D U-Net using the multimodal learn-
ing (MRI+CT) and conventional `dice was trained as the baseline model. Then
we compared the relative change of DSC, precision and recall using different
settings of `vol-dice. In the combination of two test sets, the tumors has median
1322 voxels (949 mm3) and mean 4721 voxels (3389 mm3). We tested the λc of
500, 1000, 2500, 5000 for the CR strategy.
Our baseline model achieves a DSC of 0.669, precision 0.689 and recall 0.700.
Table 1 lists the results of applying `vol-dice relative to the baseline. Overall, using
the `vol-dice with BR (λl) yields the best performance, improving 8.57% of DSC
and 24.14% of recall compared to the baseline. The performance of `vol-dice with
CR largely depends on the constant value; the higher the constant, the better the
recalls. Such an observation is consistent with our expectation that the `vol-dice
focuses more on easily neglected small structures and has a higher sensitivity.
However, in our dataset, the tumor sizes are highly diverse, therefore making it
challenging to determine a value that can generalize to all the tumors. On the
other hand, the BR approach has more flexibility using a dynamic weighting
strategy, which provides a balance between precision and recall.
`vol-dice on small tumors To evaluate the effectiveness of `vol-dice on different
sizes of lesions, we further divided the lesions into large and small tumor groups
at a cut-off point of 1500 mm3. We calculated (1) pixel-wise recall, and (2)
tumor-wise recall, where a positive tumor prediction is defined as detected if
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Table 1. Performance of different configurations with `vol-dice. All the models were
trained on 3D U-Net with CT and MRI.
`vol-dice configuration Metric Change over `dice loss (%)
Reweight method λ DSC Precision Recall
Batch-Reweight - +8.57% +2.62% +24.14%
Const-Reweight λc = 500 -52.11% +2.78% -70.08%
Const-Reweight λc = 1000 -7.67% +13.15% -18.83%
Const-Reweight λc = 2500 +2.22% -5.55% +23.04%
Const-Reweight λc = 5000 -8.60% -31.68% +25.46%
Table 2. Pixel-wise and metastasis-wise recall
Tumor Numbers Median Size Loss Pixel-wise recall Metastasis-wise recall
Small
(≤ 1500 mm3) 113 368
`dice 0.466 0.619
`vol-dice 0.633 0.672
Large
(> 1500 mm3)
78 4114
`dice 0.826 0.987
`vol-dice 0.828 0.974
there is at least one pixel being predicted; noted that we did not measure the
DSC and the precision because the false positive pixels can’t be categorized into
either small or large tumors easily. The results are shown in Table 2. `vol-dice
shows a more significant improvement in the small tumor groups, increasing the
recall from 0.466 to 0.633 and detection rate from 0.619 to 0.672; while in the
large tumor groups, the performances of the two settings are almost identical.
The results indicate that the `vol-dice effectively improve the recall in the small
tumors.
3.2 Deep Learning Framework
In our final proposed deep learning framework, we used (1) multimodal learning
adopting MRI+CT, (2) ensemble learning considering 3D U-Net and DeepMedic,
and (3) optimization using `vol-dice.
As shown in Table 3, 3D U-Net and DeepMedic obtain a DSC of 0.669 and
0.625 respectively. DeepMedic utilizes a patch-based training method, which
makes the network focusing on smaller regions and contributing to a higher
recall; on the other hand, 3D U-Net takes full resolution as inputs. The advantage
of seeing the complete brain structure leads to higher precision. The ensemble
of the two models improves the DSC to 0.719. Further applying the `vol-dice
(with BR) on 3D U-Net, we achieve the best DSC of 0.740 and recall of 0.803.
The results indicate that our deep learning approach effectively increases the
DSC, precision, and recall. The performance surpasses the current benchmark
methods. Examples of prediction results are shown in Figure 2.
3.3 Limitation
As the annotations were carried out by the neurosurgeon or radiation oncologist
during SRS treatment planning, the ground truth labels represent the area for
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Table 3. Model performance of different configurations of loss functions, image modal-
ities, and neural network models. The values are represented as median (std).
Model `vol-dice DSC Precision Recall
3D U-Net 0.669 (0.006) 0.689 (0.001) 0.700 (0.015)
DeepMedic 0.625 (0.013) 0.631 (0.004) 0.734 (0.035)
3D U-Net + DeepMedic 0.719 (0.004) 0.788 (0.002) 0.713 (0.023)
3D U-Net + DeepMedic X 0.740 (0.022) 0.779 (0.010) 0.803 (0.001)
Fig. 2. Examples of the prediction results overlaying with MRI.
Fig. 3. Examples of failed cases overlaying with MRI.
the treatment rather than the actual tumor extent, which leads to imperfect
annotations for tumor segmentation. Based on the clinician’s experience and the
patient’s disease status, these annotations can be delineated more aggressively
or conservatively. Figure 3(a) illustrates an example of an aggressive treatment
planning, which shows a broader area than the lesion. Also,the clinician would
ignore previously treated tumors (Figure 3(b)). Last, some difficult cases, such
as Figure 3(c) and (d), are highly subjective and should be determined through
clinical manifestations or the series change of MRI. The cases mentioned above
can underestimate our model performance and lead to a higher variance.
4 Conclusion
In this paper, we have achieved high performance for automated detection and
segmentation of brain metastases, utilizing multimodal imaging (MRI+CT) as
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inputs and ensemble neural networks. We have also addressed the challenge of
lesion size variance in multiple metastases by introducing a volume-aware Dice
loss, which leverages the information of lesion size and significantly enhances
the overall segmentation and sensitivity of small lesions, which are critical in the
current SRS contouring workflow. It is expected that the proposed solution will
facilitate tumor contouring and treatment planning of stereotactic radiosurgery.
References
1. Charron, O., Lallement, A., Jarnet, D., Noblet, V., Clavier, J.B., Meyer, P.: Au-
tomatic detection and segmentation of brain metastases on multimodal mr images
with a deep convolutional neural network. Computers in biology and medicine 95,
43–54 (2018)
2. C¸ic¸ek, O¨., Abdulkadir, A., Lienkamp, S.S., Brox, T., Ronneberger, O.: 3d u-net:
learning dense volumetric segmentation from sparse annotation. In: International
conference on medical image computing and computer-assisted intervention. pp.
424–432. Springer (2016)
3. Hartgerink, D.E., van der Heyden, B., De Ruysscher, D., Hoeben, A., Terhaag,
K., Lambin, P., Postma, A., Jochems, A., Dekker, A., Schoenmaekers, J., et al.:
Stereotactic radiosurgery in the management of patients with brain metastases
of non-small cell lung cancer; indications, decision tools and future directions.
Frontiers in oncology 8, 154 (2018)
4. Kamnitsas, K., Ledig, C., Newcombe, V.F., Simpson, J.P., Kane, A.D., Menon,
D.K., Rueckert, D., Glocker, B.: Efficient multi-scale 3d cnn with fully connected
crf for accurate brain lesion segmentation. Medical image analysis 36, 61–78 (2017)
5. Lin, X., DeAngelis, L.M.: Treatment of brain metastases. Journal of clinical oncol-
ogy 33(30), 3475 (2015)
6. Liu, Y., Stojadinovic, S., Hrycushko, B., Wardak, Z., Lau, S., Lu, W., Yan, Y.,
Jiang, S.B., Zhen, X., Timmerman, R., et al.: A deep convolutional neural network-
based automatic delineation strategy for multiple brain metastases stereotactic
radiosurgery. PloS one 12(10), e0185844 (2017)
7. Menze, B.H., Jakab, A., Bauer, S., Kalpathy-Cramer, J., Farahani, K., Kirby, J.,
Burren, Y., Porz, N., Slotboom, J., Wiest, R., et al.: The multimodal brain tumor
image segmentation benchmark (brats). IEEE transactions on medical imaging
34(10), 1993–2024 (2015)
8. Milletari, F., Navab, N., Ahmadi, S.A.: V-net: Fully convolutional neural networks
for volumetric medical image segmentation. In: 2016 Fourth International Confer-
ence on 3D Vision (3DV). pp. 565–571. IEEE (2016)
9. Pereira, G.C., Traughber, M., Muzic, R.F.: The role of imaging in radiation therapy
planning: past, present, and future. BioMed research international 2014 (2014)
10. Tsao, M.N., Rades, D., Wirth, A., Lo, S.S., Danielson, B.L., Gaspar, L.E., Sper-
duto, P.W., Vogelbaum, M.A., Radawski, J.D., Wang, J.Z., et al.: Radiotherapeutic
and surgical management for newly diagnosed brain metastasis (es): An american
society for radiation oncology evidence-based guideline. Practical radiation oncol-
ogy 2(3), 210–225 (2012)
11. Vinod, S.K., Jameson, M.G., Min, M., Holloway, L.C.: Uncertainties in volume
delineation in radiation oncology: a systematic review and recommendations for
future studies. Radiotherapy and Oncology 121(2), 169–179 (2016)
